T he world's population is aging, and soon the elderly population will outnumber children. 1 It is projected that the prevalence of people aged ≥65 years will triple from 524 million in 2010 to 1.5 billion in 2050 1 and that the oldest old (aged ≥85 years) will account for up to 17% of the elderly population in the developed countries. Heart disease continues to be the leading cause of death, 2 and its burden on the healthcare costs will increase proportionally with the aging population. [3] [4] [5] In the era of cost containment, it is important to understand the clinical utility, or its lack thereof, in patient populations. This would allow clinicians to determine whether testing would provide meaningful information.
The objective of this study was to understand the incremental prognostic value of positron emission tomographic (PET) myocardial perfusion imaging (MPI) in the elderly (≥85 years of age).
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
A total of 3343 patients ≥65 years old, enrolled from September 2000 to June 2009 in a multicenter observational PET registry, were analyzed. [6] [7] [8] [9] [10] Review board approval for each center was obtained, and informed consent was given for all patients. All 4 centers collected relevant medical history and PET result standardized clinical history. [6] [7] [8] [9] [10] [11] For the purpose of this study, participants were initially divided into 3 age categories: 65 to 74.9, 75 to 84.9, and ≥85 years of age (Table   I in the Data Supplement) and followed for all-cause death. Age categories 65 to 74.9 and 75 to 84.9 were similar and, therefore, combined for the analysis.
PET MPI Protocol and Image Interpretation
All patients underwent rubidium 82 PET ( 82 Rb) MPI accordingly to each center's local protocol, adhering to the American Society of Nuclear Cardiology guidelines. 12 All participants
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Image interpretation was performed using the 17-segment model to calculate summed stress score, summed difference score, and summed rest score. Using a 5-point scoring system (0, normal; 1, equivocal/mild defect; 2, moderate defect; 3, severe defect; and 4, no tracer uptake), 7, 14 patients were categorized according to total %left ventricular (LV) stress defect (ischemia and scar) into 4 categories (<5%, normal; 5%-9.9%, mild; 10%-19.9%, moderate; and ≥20%, severe) and percentage of LV ischemia (0%, normal; 0%-9%, mild; ≥10%, moderate/severe).
Follow-Up
Patients were followed for a median of 3 years (1100 days). At the United States centers, the National Death Index was used for follow-up. In Canada, follow-up was performed using telephone interviews and reviews of electronic medical records.
Statistical Analysis
Data were summarized as means (SD) for continuous variables and numbers of subjects (%) for categorical variables. χ 2 test and t test were performed to determine the significant differences. Kaplan-Meier estimator was used to estimate the survival probability among groups. The log-rank test was performed to compare the survival distributions between groups. A univariate analysis was conducted to explore the association between each predictor and outcome. Variables with P value ≤0.25 including the variable of interest and clinically important were used in the multivariable model. The Cox proportional hazards model was used to evaluate the relationship between the variable of interest and outcome after adjusting remaining variables, including interaction terms. The proportionality assumptions were checked before conducting the Cox proportional hazards model. A 2-tailed P value <0.05 was considered statistically significant. Statistical analysis was performed using Statistical Analysis System software, version 9.4 (SAS institute, Cary, NC).
RESULTS

Baseline Characteristics
Of the 3343 patients enrolled, 248 patients (49% men) were ≥85 years of age (Table I in the Data Supplement). When compared with younger patients, individuals ≥85 years of age had a higher prevalence of hypertension (79%). Dyslipidemia was present in 54%, diabetes mellitus in 24%, and history of coronary artery disease in 40% of those ≥85 years of age. All-cause death was the highest in the ≥85-year category.
The %LV ischemia was lower in patients ≥85 years of age, and the %LV stress defect was higher in older patients (Table 1) . Of patients ≥85 years of age, 141 patients had a normal/equivocal, 39 had mild, 39 had moderate, and 29 had severely abnormal stress perfu- sion defects. One hundred twenty-nine patients had no ischemia, 78 had mild ischemia, and 41 had moderate/ severe ischemia.
Clinical Variables and PET MPI Result Impact on Survival
On multivariable analysis, %LV stress defect categories were predictors of all-cause death in those aged 65 to 84.9 years, but this was not observed in those ≥85 years of age (Table 2) . Similarly, %LV ischemia had prognostic value in those with 65 to 84.9 years of age but was not statistically significant in those ≥85 years of age (Table 3) . Annual death rate for patients 65 to 84.9 years of age increased significantly with increasing in %LV ischemia and %LV stress defect, but the same was not observed for patients ≥85 years of age. Patients ≥85 years of age, despite PET results, had high annual death rates that were similar to or greater than those <85 years with moderate-to-severe ischemia and %LV stress defects ≥10% (Table 4) .
The prognostic value of PET (%LV stress defect and ischemia) appears to decrease with advancing age ( Figure 1 ) and was similar between men and women.
Cumulative survival curves for patients 65 to 84.9 years of age for %LV stress defect (Figure 2A ) and %LV ischemia ( Figure 2B) showed that survival was inversely related to severity of disease. A similar trend was observed in those ≥85 years of age but was not statistically significant ( Figure 3A and 3B) .
DISCUSSION
As healthcare costs continue to increase, it is important to understand the utility of testing and its value in different populations. As the population continues to age, it is important to determine whether an age threshold exists, where testing may no longer provide prognostic value. The results of our study suggest that patients ≥85 years of age are a high-risk population irrespective of %LV stress defect. In patients ≥85 years of age, %LV stress defects between 5% to 9.9% and 10% to 19.9% did not have incremental prognostic value (hazard ratio [HR], 0.78 and 0.77, respectively). A trend was observed in those with %LV stress defect ≥20%, but this did not reach statistical significance (HR, 1.62; P=0.37).
Previous studies have examined the value of treadmill testing and single-photon emission computed tomography in the elderly. One study demonstrated that the Duke treadmill score did not predict cardiac death or myocardial infarction in patients Figure 2 . Kaplan-Meier survival curves for patients 65 to 84.9 y old. A, Survival stratified by %left ventricular (LV) stress defect categories (<5%, blue line; 5%-9.9%, red line; 10%-19.9%, green line; and ≥20%, brown line) and (B) by %LV ischemia (0%, blue line; 1%-9%, red line; and ≥10%, green line).
>75 years of age. 15 However, single-photon emission computed tomographic MPI, in the elderly, showed prognostic value in those with high-risk ischemia. [16] [17] [18] [19] Valeti studied 247 patients ≥75 years of age who underwent thallium-MPI and found that low-and high-risk patients (summed stress score ≤3 and ≥9, respectively) had annual cardiac mortality rates of 0.8% and 5.8% (P<0.001), respectively. 19 Hachamovich studied 5200 patients >75 years of age and found that abnormal MPI and normal LV ejection fraction (LVEF) were associated with higher cardiac death rates when compared with patients with normal MPI and normal LVEF (HR, 1.88; confidence interval, 1.18-3.0). 17 Similarly, normal MPI and abnormal LVEF had an HR of 3.17 for cardiac events, whereas abnormal MPI and abnormal LVEF had an HR of 5.71 (95% confidence interval, 1.80-5.58 and 3.92-8.32, respectively), suggesting that MPI result was able to provide risk stratification and had incremental prognostic value. 17 Nair et al studied the elderly (>80 years of age) and still found significant difference in annual cardiac event rates (cardiac death and nonfatal myocardial infarction) across summed stress score categories (normal, 2.5%; mildly abnormal, 3.4%; and moderate-toseverely abnormal, 9.6%; P<0.001).
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Our study examines the elderly (≥85 years of age) using superior technology and suggests the prognostic value may begin to wane in the elderly. These patients, irrespective of MPI results, were at high risk and had rates similar to the highest risk patients between 65 and 85 years of age. The fact that the prognostic value of PET may decrease in those ≥85 years of age suggests that further studies are need to better understand the utility of imaging and testing in the oldest population. Determining an age threshold at which testing may no longer provide meaningful incremental information would be important for resource and fiscal management.
Limitations
Data from the multicenter observational PET registry were used retrospectively to assess the prognosis of PET MPI in the elderly. The authors acknowledge that there is likely variability in patient management after the PET MPI because of the multiple centers involved. Although this information was not available, these results may actually reflect the real-world application and translation of imaging results. Information on cardiac versus noncardiac death was not available, and thus, the analysis was performed using all-cause death. In addition, we lacked LVEF data and thus could not be included in the multivariable analysis. We also lacked information on patient noncardiac comorbidities and therapies, and this may limit our ability to translate our findings to other elderly populations. Irrespective, the reduction in the prognostic value of PET suggests that this elderly population is at high risk irrespective of MPI results. Although the total population was >3300 patients, the population of those ≥85 years of age was relatively small. Though this is the largest study of its kind, this study may have been underpowered to detect the true benefit of PET in those ≥85 years of age, and larger studies are still needed. Although all-cause death was used as the primary outcome in all age categories, the impact of revascularization impact was not assessed in this study and may have reduced the power to detect the prognostic value of PET in patients ≥85 years of age.
Conclusions
The elderly is a high-risk population irrespective of PET MPI results, and incremental prognostic value of PET MPI appears to wane in those ≥85 years of age. Although PET MPI may be diagnostically useful in the elderly, its prognostic value in this population requires further evaluation.
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